Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as tirapazamine (SR259075), SR259075
tirapazamine · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Tirapazamine + Cisplatin | EXPERIMENTAL | - |
| Cisplatin | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Tirapazamine | DRUG | in combination with cisplatin and concomitant radiation |
| Cisplatin | DRUG | with concomitant radiation |
| tirapazamine (SR259075) | DRUG | - |
| Radiation Therapy | PROCEDURE | - |
| vinorelbine tartrate | DRUG | - |
Inclusion Criteria: * Previously untreated squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. * Stage III or IV disease (excluding T1N1, and T2N1 and metastatic disease). * Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2. * Absolute ...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
Tirapazamine has been studied in head and neck neoplasms, head and neck squamous cell carcinoma, and lung cancer. It is an oncology small molecule developed by Sanofi. It is investigational and has not been approved for these indications. Clinical development reached Phase 3, and the trials testing it in these cancer types are completed.
Tirapazamine is developed by Sanofi, which trades under the ticker SNY. Sanofi sponsored the Phase 3 clinical program evaluating the drug in head and neck cancer and in non-small cell lung cancer. The company is the developer associated with the tirapazamine trials.
Tirapazamine reached Phase 3 clinical development. Three Phase 3 trials were conducted in head and neck squamous cell carcinoma, head and neck neoplasms, and non-small cell lung cancer, and all are completed. Tirapazamine is investigational and is not an approved therapy.
Tirapazamine was evaluated in Phase 3 trials including NCT00174837, the TRACE study of tirapazamine, radiation, and cisplatin in head and neck squamous cell carcinoma, and NCT00094081, which tested concomitant radiation and cisplatin with and without tirapazamine in advanced head and neck cancer. NCT00017459 studied cisplatin plus vinorelbine with or without tirapazamine in stage IIIB or IV non-small cell lung cancer.
Yes, tirapazamine is also known as SR259075. SR259075 is an alternative designation used for the same investigational oncology small molecule. Readers searching for either name are looking at the same Sanofi compound studied in head and neck cancer and lung cancer trials.
The tirapazamine Phase 3 program enrolled patients across its studies, including 861 participants in NCT00094081 and 317 participants in the TRACE trial, NCT00174837. The trials were randomized and conducted in adults aged 18 years and older, with enrollment recorded across multiple countries.